The Economic Impact on Australian Patients with Neuroendocrine Tumours

`Little is known about the economic burden to patients and families with neuroendocrine tumours (NETs) for medical out-of-pocket expenses and employment decisions. This study was preformed to determine the extent and factors influencing the financial consequences of living with NETs and their effect on quality of life’.

We are so grateful to the more then 200 Australian NET patients who participated in the study, with the results presented in poster form at this years annual European Neuroendocrine Tumour Society (ENETs) meeting.

The study looked at a variety of costs and “highlighted the dual problem of cumulative out-of-pocket costs and early unanticipated retirement from the workforce.”

We will be using this information and looking at more prospective data as advocate to reduce costs for our patients. Well done to the authors including; Louise Gordan, Thomas Elliott, Kate Wakelin, Simone Leyden, John Leyden, Michael Michael, Nick Pavlakis, Jan Mumford, Eva Seglaov and David Wyld.

To read the article in full please click below on the paper.

Click Below to Read On


FNETs

Share this article

Subscribe to our Newsletter

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Related News

NECA CEO Meredith Cummins is Now INCA President

NECA Contributes to Multidisciplinary Systemic Review

Celebrated Chef and Slow Food Pioneer Skye Gyngell Passed Away from Neuroendocrine Cancer

NECA Christmas and New Year Closure Details

Walk, run, or ride this March4NETs!

For its third year, March4NETs will run throughout March 2026.

Get involved and support the 31,000 Australians living with neuroendocrine cancer.